XFOR · X4 Pharmaceuticals, Inc
$4.04
+0.01 (+0.25%)
At close · Aug 21
Market Cap
$399.56M
Shares
99.15M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.04
Open$4.05
Day$4.01–4.18
52W close$2.86–4.67
Avg vol 30d703K
Short int7.3M · 7.4% float · 12.8d
Short vol14%
Last earningsMay 1, 2025
DataApr 2025–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Apr 28, 2025; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
−1%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
65%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+19%
trailing
YTD return
+1%
this year
Relative strength
+7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +32 funds added
Insider flow
Distributing
Net -$356.5K over 90 days · 100% sells
Short interest
Rising
7.36% of float · ▲ +12.3% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
89 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+150%
Y/Y
EPS growth
+67%
Y/Y
Free cash flow
$-85.9M
Balance sheet
$162.5M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−38%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
65%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +32 funds added
Insider flow
Distributing
Net -$356.5K over 90 days · 100% sells
Short interest
Rising
7.36% of float · ▲ +12.3% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
89 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $4 · 65%
Range high $5
vs 200-day avg +3%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XFOR
this stock
X4 Pharmaceuticals, Inc
|
$399.56M | +1.0% | +150.0% | — | 7.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +20.9% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Apr 28, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XFOR | -4.3% | +4.9% | +18.8% | +1.5% | +1.0% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -2.9% | +1.3% | +7.3% | -1.0% | -11.3% |
Key facts
CIK
1501697
CUSIP
98420X202
13F (30d)
90 filings
87 filers
Visit website
Investor relations